EurekaMag
+ Translate
+ Most Popular
Sympathetic and visceral nerve blocks
What should be done after bee or wasp stings?
Anti-drool cheiloplasty: clinical results in six dogs
The biology of human starvation: some new insights
Vitamin B12 deficiency as a worldwide problem
Effect of daily gelatin ingestion on human scalp hair
On the nature and role of vivotoxins in plant disease
History of the discovery of vitamins by N. I. Lunin
Preliminary tests with residual sprays against poultry lice
MDU.1, a new mutant chilli variety
A study on compatibility of some insecticides with a fungicide on small cardamom (Elettaria cardamomum Maton.)
The cranial nerves of Mystus seenghala (Sykes)
The effects of prefrontal lobotomy on aggressive behavior in dogs
Human monkeypox: disease pattern, incidence and attack rates in a rural area of northern Zaire
The identity of the lipstick mold of cultivated mushrooms agaricus bisporus
Therapy for acne with saccharomyces boulardii
Advantages and disadvantages of bordeaux mixture and of lime-sulphur used on apples in the growing season
The composition of pampas-grass (Cortaderia argentea.)
Productivity of Pekin x Khaki Campbell ducks
A rapid survey of katydids (Insecta: Orthoptera: Tettigoniidae) of the Foret Classee du Pic de Fon, Guinea
Cranial nerves of Labeo rohita (Ham.)
Evaluating fundamentals of care: The development of a unit-level quality measurement and improvement programme
Life-cycle of the free-living nematode Pontonema vulgare in the White Sea
Grey leaf blight - a new disease of cocoa
Effect of foliar spray of urea and zinc sulphate on yield and fruit quality of Kinnow - 'a mandarin hybrid'

Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies


Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies



Journal of Immunology 167(7): 4059-4066



ISSN/ISBN: 0022-1767

PMID: 11564827

DOI: 10.4049/jimmunol.167.7.4059

Expression of CD137 ligand (4-1BBL), a member of the TNF family of proteins, has been reported on several types of APCs, various carcinoma cells, and can be induced on activated T cells. In this study, we report that the soluble ligand was released constitutively at low levels from leukocytes and at higher levels following cellular activation. Release from cells was blocked by addition of a metalloproteinase inhibitor which concomitantly caused the accumulation of 4-1BBL on the cell surface. In addition, we show that a soluble form of 4-1BBL was present at high levels in the sera of some patients with various hematological diseases, but only at low levels in healthy donors. Soluble 4-1BBL was active in that it competed with recombinant 4-1BBL for binding to the 4-1BB receptor and was able to costimulate IL-2 and IFN-gamma release from peripheral T cells. These results indicate that the release of soluble 4-1BBL from the cell surface is mediated by one or more sheddases and likely regulates 4-1BB-4-1BBL interactions between cells in vivo. Cleavage of 4-1BBL to an active soluble form would alter both proximal and distal cellular responses, including cell survival and costimulatory or inflammatory responses, that are mediated through the 4-1BB pathway. This, in turn, would likely alter disease progression or outcome.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 018120570

Download citation: RISBibTeXText

Related references

Measurement of Soluble Interleukin 2 Receptor in Sera of Adult Patients with Hematological or Solid Malignancies. Leukemia and Lymphoma 3(5-6): 385-393, 1991

The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy. Zhonghua Xue Ye Xue Za Zhi 38(12): 1066-1068, 2017

Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detection and Prevention 29(3): 256-259, 2005

Soluble CD40 ligand in sera from patients with SLE is present at concentrations that can mediate B cell activation. Arthritis and Rheumatism 41(9 Suppl. ): S235, 1998

Prevalence of antibodies to Hepatitis A antigen in sera from patients with haematological malignancies. Journal of Medical Virology 8(1): 49-53, 1981

A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. European Journal of Immunology 25(6): 1749-1754, 1995

Levels of soluble FAS but not soluble Fas ligand were elevated in the sera of patients with SLE. Arthritis and Rheumatism 39(9 Suppl. ): S44, 1996

Development of an ELISA assay for soluble CD35 (C3b/C4b receptor): high levels of soluble CD35 in LE-positive patients with hematological malignancies. Immunology Letters 41(2-3): 249-253, 1994

Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease. Clinical Rheumatology 26(3): 393-400, 2007

Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leukemia and Lymphoma 45(10): 2111-2118, 2004

The role of soluble HLA-G and HLA-G receptors in patients with hematological malignancies after allogeneic stem cell transplantation. Medical Oncology 32(8): 219, 2015

Comparison of galactomannan, beta-D-glucan, and Aspergillus DNA in sera of high-risk adult patients with hematological malignancies for the diagnosis of invasive aspergillosis. Turkish Journal of Medical Sciences 46(2): 335-342, 2016

Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1α, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies. Cell Biochemistry and Biophysics 27(1): 1-14, 1995

The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy. Zhonghua Xue Ye Xue Za Zhi 41(3): 210-215, 2020

Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2. Archivum Immunologiae et Therapiae Experimentalis 45(5-6): 443-448, 1997